selective degrader of IRAK3 pseudokinase

in vitro degradation in primary macrophages

from mining of internal kinase inh. and linking

J. Med. Chem., Sep. 24, 2020

AstraZeneca, Waltham, MA / Cambridge, UK

“compound 23” is a selective CRBN-based degrader of the pseudokinase, IRAK3, with in vitro activity in primary human cells. A volcano plot shows remarkable separation between IRAK3 degradation vs. most…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks